Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:43:48 EST Thu 05 Dec 2024
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:EOLS from 2023-12-06 to 2024-12-05 - 38 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-11-06 16:05U:EOLSNews ReleaseEvolus Reports Third Quarter 2024 Results
2024-11-01 08:00U:EOLSNews ReleaseEvolus to Participate in Stifel 2024 Healthcare Conference
2024-10-31 14:02U:EOLSNews ReleaseEvolus Announces EU Approval of Estyme(TM) Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
2024-10-29 08:00U:EOLSNews ReleaseEvolus Rewards(TM) Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
2024-10-23 08:00U:EOLSNews ReleaseEvolus to Report Third Quarter Financial Results on November 6, 2024
2024-10-11 22:53U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-27 21:00U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-06 08:00U:EOLSNews ReleaseEvolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
2024-08-09 16:30U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-07-31 16:05U:EOLSNews ReleaseEvolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
2024-07-31 08:00U:EOLSNews ReleaseEvolus to Hold Investor Day on September 12, 2024
2024-07-30 08:00U:EOLSNews ReleaseEvolus Expands Global Footprint with Introduction of Nuceiva(TM) (botulinum toxin type A) in Australia
2024-07-25 08:00U:EOLSNews ReleaseEvolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
2024-07-17 08:00U:EOLSNews ReleaseEvolus to Report Second Quarter Financial Results on July 31, 2024
2024-07-01 08:00U:EOLSNews ReleaseEvolus Announces Appointment of Albert G. White III to Board of Directors
2024-06-24 08:00U:EOLSNews ReleaseEvolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse(TM) Dermal Filler Products
2024-06-12 08:00U:EOLSNews ReleaseEvolus Broadens International Presence with Launch of Nuceiva(TM) (botulinum toxin type A) in Spain
2024-06-07 17:00U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-20 08:30U:EOLSNews ReleaseEvolus Announces Positive Data from Pivotal Trial for First Two Evolysse(TM) Dermal Filler Products at 2024 SCALE Meeting
2024-05-10 18:55U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-10 09:10U:EOLSNews ReleaseEvolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year
2024-05-07 16:05U:EOLSNews ReleaseEvolus Reports First Quarter 2024 Results and Provides Business Update
2024-04-23 16:30U:EOLSNews ReleaseEvolus to Report First Quarter Financial Results on May 7, 2024
2024-04-17 16:05U:EOLSNews ReleaseEvolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau(TM)
2024-04-12 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-26 08:00U:EOLSNews ReleaseEvolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2024-03-11 07:00U:EOLSNews ReleaseEvolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
2024-03-08 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-07 16:05U:EOLSNews ReleaseEvolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
2024-03-01 08:30U:EOLSNews ReleaseEvolus Announces Results from European Head-to-Head Filler Trial
2024-02-27 08:30U:EOLSNews ReleaseEvolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
2024-02-22 16:30U:EOLSNews ReleaseEvolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
2024-02-09 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-16 17:28U:EOLSNews ReleaseEvolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
2024-01-12 16:23U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-04 16:05U:EOLSNews ReleaseEvolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
2023-12-20 08:00U:EOLSNews ReleaseEvolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
2023-12-08 16:30U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)